Cytokinetics, Inc. (CYTK)

NASDAQ: CYTK · IEX Real-Time Price · USD
43.90
+2.90 (7.07%)
At close: Jul 5, 2022 4:00 PM
43.27
-0.63 (-1.44%)
Pre-market: Jul 6, 2022 7:07 AM EDT

Company Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.

The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial.

Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Inc.
Cytokinetics Logo
Country United States
Founded 1997
IPO Date Apr 29, 2004
Industry Biotechnology
Sector Health Care
Employees 253
CEO Robert Blum

Contact Details

Address:
280 E Grand Ave
South San Francisco, California 94080-4808
United States
Phone 650 624 3000
Website cytokinetics.com

Stock Details

Ticker Symbol CYTK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001061983
CUSIP Number 23282W100
ISIN Number US23282W6057
Employer ID 94-3291317
SIC Code 2834

Key Executives

Name Position
Robert I. Blum Chief Executive Officer, President and Director
Ching W. Jaw Senior Vice President and Chief Financial Officer
Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Executive Vice President of Research & Development
Andrew M. Callos Executive Vice President and Chief Commercial Officer
Dr. James A. Spudich Ph.D. Co-Founder and Member of Scientific Advisory Board
Jeff Lotz Vice President of Sales and Operations
Robert C. Wong Vice President and Chief Accounting Officer
David W. Cragg Chief Human Resources and Administrative Officer
Joanna Siegall Associate Director of Corporate Communications and Investor Relations
Kari K. Loeser J.D. Vice President and Chief Compliance Officer

Latest SEC Filings

Date Type Title
Jun 24, 2022 8-K Current report
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 8-K Current report
Jun 16, 2022 8-K Current report
Jun 13, 2022 8-K Current report
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 8, 2022 4 Statement of changes in beneficial ownership of securities
May 31, 2022 S-8 Securities to be offered to employees in employee benefit plans
May 27, 2022 8-K Current report
May 23, 2022 8-K Current report